Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma.
J Clin OncolAug 25, 2026 (epub)
Clinical ResearchOncology (Medical)
Dan-Yun Ruan, Feng-Hua Wang, Yujuan Zhou et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase I/II clinical trial evaluated the combination of becotatug vedotin (BV) and pucotenlimab in patients with platinum- and immunotherapy-resistant recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). Among 31 patients, the confirmed objective response rate (ORR) was 71.0%, with a disease control rate (DCR) of 93.5%.
Key findings
- Confirmed ORR was 71.0% (95% CI, 52.0 to 85.8) in treated patients.
- DCR reached 93.5% (95% CI, 78.6 to 99.2).
- Median duration of response was 14.0 months (95% CI, 5.7 to not estimated).
- 40.6% of patients experienced treatment-related adverse events of grade 3 or higher.
Why it matters
The study highlights a potential new treatment strategy for patients with limited options after failing standard therapies, demonstrating significant efficacy and manageable safety profiles.